GLOBAL MARKET TRENDS The view from Pharma By Peter Knauer Executive Partner, Alliance Partnership.

Slides:



Advertisements
Similar presentations
1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.
Advertisements

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Future Challenges Nigel Edwards Policy Director, NHS Confederation Visiting Professor London School of Hygiene and Tropical Medicine.
Funding Excellence in Research Mark Walport 2 December 2010.
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
Making dementia a European priority Marseille – 17 October 2008 Jean Georges, Executive Director.
CDC Welcomes Institute for Quality in Laboratory Medicine Toby L. Merlin, MD Director, Division of Private and Public Partnerships National Center for.
Reorganization of APHIS Veterinary Services U.S. Department of Agriculture Animal and Plant Health Inspection Service Veterinary Services November 2013.
EMAS III: A mature instrument for new challenges Soledad BLANCO Director, Directorate Industry DG Environment.
Step up your competitiveness Focus on innovative solutions Look at growth; not on short term lossesUnderstand the underlying dynamics of the marketplace…..
Antimicrobial resistance “One health fits all”
Texas Workforce Commission The Texas Workforce Commission (TWC) is a collaborating partner in the economic development processes for the State of Texas.
The NIH Roadmap for Medical Research
Urban-Nexus – Integrated Urban Management David Ludlow and Michael Buser UWE Sofia November 2011.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
The involvement of patients in Health Technology Assessment Andrzej Rys Director Health and Consumers Directorate-General Brussels 18 May 2010.
FORESIGHT STUDY Future Trends and Challenges in Pathogenomics JUDITH SIMON & SVEN POMPE PROGRAMME GROUP MUT.
Horizon 2020 The EU Framework Programme for Research and Innovation Health, Demographic Change and Wellbeing Lul Raka, NCP for Horizon 2020 – Health.
Director, DG RTD, Directorate International Cooperation
World Health Organization Department of Chronic Diseases and Health Promotion World Health Organization Global Perspective on Health Promotion Tang Kwok-cho.
A National Approach to Cancer Control in Canada Remarks by Jeff Lozon, Chair Canadian Partnership Against Cancer.
A project implemented by the HTSPE consortium This project is funded by the European Union SECURITY AND CITIZENSHIP.
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
| International Clinical Trials Registry Platform1 Innovation of New Antibiotics WHO Technical Briefing Seminar Zafar Mirza 04 November 2014 WHO, Geneva.
Click to edit Master title style Click to edit Master text styles Second level Third level Fourth level Fifth level SIMS Overview ©2005 The Sims Project.
Published By: Zion Research U.S. Pet Food (Dry Fo d, Wet Food and Treat & Snacks/Mixers) Market for Dogs, Cats and Other Pets Joel John 3422.
Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.
Peter B. Bloland, DVM, MPVM Director Division of Public Health Systems and Workforce Development Global Health Leadership Forum November 10, 2011 National.
Policy Research and Innovation Research and Innovation Enhancing and focusing EU international cooperation in research and innovation: A strategic approach.
Establishing Defra’s evidence needs Dr Steven Hill Chief Scientific Adviser’s Secretariat, Science Directorate.
Horizon 2020 First reflections Tallinn
Science Policy and Social Change Michael Crow May 2003.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Annual Meeting of the ASADI – Science Academies as Partners for Improving the Impact of Policies in Africa Session V: Partnership Themes for Development.
Towards an European Network of Earth Observation Networks (ENEON): Addressing Challenges and Facilitating Collaboration for non-space based Earth Observations.
HORIZON 2020 SC1-Health, demographic change and wellbeing challenge Марина Николовска Министерство за образование и наука
EC actions against the rising threats from Antimicrobial Resistance
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Washington State Alzheimer’s Plan Senior Lobby October 28, 2015.
Emily Nott Relationship Manager - Research Councils IT Community Summit 3 April 2008 Technology Strategy Board V
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
Perspectives on containing antimicrobial resistance – ways to go … Karl Ekdahl, Strategic Advisor on behalf of Zsuzsanna Jakab, Director European Centre.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
IncoNet EaP is a project funded under the 7th European Framework Programme for research - Project number EU-Eastern Partnership STI Cooperation.
1 Outcome of the 4 th Global Animal Health Conference (GAHC) June 2015 Bettye K. Walters, DVM US Food and Drug Administration
Driving Innovation Making the UK a global leader in innovation Merlin Goldman 8 September 2011.
Health and Food Safety EU strategy for Pharmaceuticals in the Environment Patrizia Tosetti DG SANTE European Commission China/EU Pharmaceutical Industry.
An agency of the European Union Sharing Our Vision? A view from the European Medicines Agency PGEU Symposium, 17 June 2013, Rome Presented by: Guido Rasi.
Slide 1 Encouraging innovation: the regulators perspective Bringing the best to healthcare through partnership and innovation IPHA, 1 st December 2011.
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
The Insurance Industry in Uganda, Key Trends and Opportunities to 2018 Market Research Report ©reportscue.
AGE WORKS - HOW THE NORTH WEST OF ENGLAND IS EMBRACING DEMOGRAPHIC CHANGE.
I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.
CONFIDENTIAL 0 0 Paul Stoffels, M.D. Chief Scientific Officer Worldwide Chairman, Pharmaceuticals.
CIS 170 MART Teaching Effectively/cis170mart.com FOR MORE CLASSES VISIT HCA 497 MART Inspiring Minds/hca497mart.com FOR MORE CLASSES.
Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.
Mobile money – The next wave of growth Optimizing operator approaches in a fast – changing landscape 엄영범 – 부교재 발표 김민재 – 본교재 발표.
Anne-Marie Yazbeck, PhD National Infoday, Sweden 2017
A capacity building programme for patient representatives
State of the TB Alliance
Community Pharmacy: Sharing Our Vision
Finland, a Global Testbed for Personalized Cancer Research?
"Ageing Societies" – A global challenge and shared- opportunity
International Cooperation
EXPLORING GLOBAL COOPERATION OPPORTUNITIES
Future Innovation in Animal Diagnostics
An introduction to EMA’s support for medicines development
BioCapital Europe 2019, Amsterdam
Expert Speak: How Pharma Companies Can Grow Their Business?
Presentation transcript:

GLOBAL MARKET TRENDS The view from Pharma By Peter Knauer Executive Partner, Alliance Partnership

Area of Focus: European Union EU Medicines Agencies Network Strategy to high level strategy for the network for the next 5 years

Strategic Overview EMA Says: “The medicines that we regulate are changing as our understanding of the scientific basis for disease evolves. We are seeing new diseases emerge and existing diseases redefined. Old problems such as antimicrobial resistance have become major public health threats and existing and new infectious diseases require new therapies. As the population ages, diseases such as dementia become more of a public health burden. New technologies are emerging and personalized medicines will represent an increasing part of the armamentarium. We are seeing new advanced therapies and more combination and borderline products.”

Goals for the Next Five Years This presnetation outlines the high level strategy for the EU network for the next 5 years. EU is presenting this for the first time as a single strategy for the entire network to reflect the need for a coordinated approach to address the multiple challenges and opportunities that face the network. Advances in science affect the nature of the products regulated and the network must support new and innovative developments that contribute to public health. There is a need for efficiency and transparency, the need to address new and emerging threats, whether of a public health or criminal nature, and the need to work globally with other regulators given the increasing globalization of the pharmaceutical industry.

Theme 1: Contributing to Human Health

Theme 2: Contributing to Animal Health and Human Health in Relation to Veterinary Medicines

Theme 3: Optimizing the Operation of the Network

Theme 4: Contributing to the global regulatory environment

Summary EU is embacing change Look at ISO 9001 as an example – “impovement” is a key princlple. New 5 year strategy has been developed Expect significant change to regulations to keep up with modern issues.